Orphazyme A/S (ORPH)

Trade ORPH now with
8/31/2021 1:05:36 AM Orphazyme H1 Net Loss DKK 463.8 Mln Or DKK 13.27/Shr Vs Loss Of DKK 251.4 Mln Or DKK 9.77/Shr Last Year
8/24/2021 8:05:30 AM CytRx Highlights Orphazyme's Published Results From Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C
6/28/2021 12:37:57 AM Orphazyme Announces Restructuring To Focus Resources On Supporting Path Forward For Arimoclomol
6/18/2021 2:03:01 AM Orphazyme Receives CRL From FDA Following Review Of NDA For Arimoclomol
3/29/2021 2:34:30 AM Orphazyme Says Phase 2/3 Trial Evaluating Arimoclomol Did Not Meet Primary, Secondary Endpoints
3/2/2021 1:05:03 AM Orphazyme FY Net Loss DKK 633.2 Mln Vs Loss Of DKK 337.5 Mln Last Year
3/1/2021 1:08:58 AM Orphazyme Appoints Christophe Bourdon As CEO, Effective As Of April 1, 2021